Nicotinamide Riboside in a Parkinson’s Patent
A Parkinson’s patent publication explicitly names nicotinamide riboside, but the dossier does not establish dose, route, disease stage, patient group, or clinical support.
Nicotinamide Riboside in a Parkinson’s Patent
The patent publication Nad-augmentation therapy for parkinson's disease - Google Patents explicitly says: “nicotinamide riboside for use in a method for treatment of Parkinson’s disease.”
So this is not vague “NAD is probably good for things” talk. It is a Parkinson’s-specific claim that names nicotinamide riboside.
Nicotinamide Riboside is an NAD precursor used to raise NAD availability.
But a patent is not proof of benefit. The dossier does not establish dose, route, disease stage, patient group, or clinical support. Paperwork exists. Proven effect does not.
Read next: Nicotinamide Riboside | WO2022269066A1 patent
Sources
Nad-augmentation therapy for parkinson's disease - Google Patents
Selected because it is a concrete, non-vague connection: a well-known NAD precursor appears by name inside a Parkinson’s-specific patent publication, which gives readers something real to inspect without pretending it proves efficacy.